A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation
Abroad (travel likely)Recruiting
Conditions
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
First Affiliated Hospital of Kunming University, Kunming, Yunnan, China